Nebivolol is a beta blocker used to treat high blood pressure and heart failure.
This report contains market size and forecasts of Bystolic (Nebivolol) ( CAS 99200-09-6) in global, including the following market information:
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Bystolic (Nebivolol) ( CAS 99200-09-6) companies in 2021 (%)
The global Bystolic (Nebivolol) ( CAS 99200-09-6) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
5 mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bystolic (Nebivolol) ( CAS 99200-09-6) include Allergan plc (AbbVie Inc.), Mylan Laboratories, Actavis Generics (Teva), Zydus Healthcare Ltd, Eris lifesciences, Cipla ltd, Lupin ltd, Abbott and Cadila Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bystolic (Nebivolol) ( CAS 99200-09-6) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Segment Percentages, by Type, 2021 (%)
5 mg
10 mg
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Segment Percentages, by Application, 2021 (%)
Hypertension
Heart Failure
Others
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bystolic (Nebivolol) ( CAS 99200-09-6) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Bystolic (Nebivolol) ( CAS 99200-09-6) revenues share in global market, 2021 (%)
Key companies Bystolic (Nebivolol) ( CAS 99200-09-6) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Bystolic (Nebivolol) ( CAS 99200-09-6) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan plc (AbbVie Inc.)
Mylan Laboratories
Actavis Generics (Teva)
Zydus Healthcare Ltd
Eris lifesciences
Cipla ltd
Lupin ltd
Abbott
Cadila Pharmaceuticals